Keyphrases
Chronic Urticaria
79%
Omalizumab
78%
Chronic Spontaneous Urticaria
42%
Hidradenitis Suppurativa
37%
Disease Activity
30%
Comorbidity
27%
Patient-reported Outcomes
27%
Adalimumab
25%
Quality of Life
24%
Treatment Response
20%
Older Women
18%
Antihistamines
17%
Biologic Therapy
16%
Rheumatoid Arthritis
14%
Chronic Inflammatory Diseases
14%
Risk Factors
14%
Psoriasis
14%
Hospital-based Cohort
12%
Aftermarket
12%
Secukinumab
12%
Cholinergic Urticaria
12%
Melanoma Metastasis
12%
Temporal Relations
12%
Malignant Melanoma
12%
Ustekinumab
12%
Sequential Treatment
12%
Nationwide Registry
12%
Moderate-to-severe Psoriasis
12%
Factors Affecting Quality
12%
Recent History
12%
Hair Loss
12%
Blood Biomarkers
12%
Disease Treatment
12%
Mental Disorders
12%
Treatment Monitoring
12%
D-dimer
12%
Occurrence Factor
12%
Patient Selection
12%
Periodontitis Treatment
12%
Systematic Literature Review
12%
Serum Levels
12%
Etanercept
12%
Combined Treatment
12%
Infliximab
12%
Diabetes
10%
Hurley Stage
9%
Skin Diseases
9%
Serum Concentration
9%
Body Mass Index
9%
Dermatology Life Quality Index
8%
Medicine and Dentistry
Chronic Urticaria
87%
Omalizumab
53%
Hidradenitis Suppurativa
37%
Biological Marker
27%
Patient-Reported Outcome
27%
Treatment Response
26%
Quality of Life
22%
Disease
20%
Disease Activity
20%
Side Effect
17%
Biological Therapy
16%
Histamine Antagonist
15%
Psoriasis
14%
Cohort Analysis
13%
D-Dimer
12%
Metastatic Melanoma
12%
Prospective Study
12%
Nodular Melanoma
12%
Ustekinumab
12%
Combination Therapy
12%
Secukinumab
12%
Periodontitis
12%
Adalimumab
12%
Diabetes
10%
Dermatosis
9%
Dermatology Life Quality Index
8%
Urticaria
8%
Brain Metastasis
6%
Inflammatory Disorder
6%
Malignant Neoplasm
6%
Body Mass Index
5%
Symptom
5%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Urticaria
100%
Omalizumab
78%
Disease
30%
Biological Marker
25%
Psoriasis
25%
Prospective Study
25%
Side Effect
24%
Disease Activity
23%
Antihistaminic Agent
17%
Rheumatoid Arthritis
14%
Comorbidity
12%
Secukinumab
12%
Hair Loss
12%
Melanoma
12%
Cholinergic Urticaria
12%
Metastatic Melanoma
12%
Infliximab
12%
Etanercept
12%
Ustekinumab
12%
Inflammatory Disease
12%
Adalimumab
12%
D Dimer
12%
Combination Therapy
12%
Adverse Event
9%
Urticaria
8%
Prevalence
7%
Skin Disease
7%
Brain Metastasis
6%
Malignant Neoplasm
6%